丙泊酚干扰基于aPTT的治疗性肝素抗凝监测
该回顾性观察性队列研究纳入38例同时接受丙泊酚和肝素输注的ICU患者,共531次aPTT检测,发现109次aPTT(21%)覆盖21例患者(55%)存在 documented 干扰,其中12次aPTT因干扰无法报告;所有干扰均非溶血或高胆红素血症所致,超速离心可消除多数光学干扰但显著延迟报告。
要点
- 丙泊酚与肝素联用时约55%患者出现aPTT检测干扰,21%的aPTT结果受影响。
- 干扰非溶血或高胆红素所致,超速离心可去除多数光学干扰但延长报告时间。
- 临床需警惕丙泊酚对光学法aPTT的干扰,避免因此延误肝素剂量调整。
核心结论
- 在接受丙泊酚与肝素联合输注并监测aPTT的患者中,约半数观察到潜在的药物-检测方法相互作用。
研究设计与样本
- 回顾性观察性队列研究,纳入ICU中同时接受丙泊酚和肝素输注且以aPTT监测肝素治疗的患者38例,共531次aPTT检测。
主要发现
- 109次aPTT(21%)覆盖21例患者(55%)存在记录的aPTT干扰。
- 21例患者均至少有一次aPTT需在报告前进行超速离心,4例患者的12次aPTT因干扰无法报告。
- 有干扰与无干扰患者的丙泊酚剂量相似。
- 无一例aPTT干扰由溶血或高胆红素血症引起。
关键数值与推荐
- aPTT干扰率:109/531次(21%);受影响患者:21/38例(55%)。
- 12次aPTT因干扰无法报告,涉及4例患者。
临床怎么用
- 对同时接受丙泊酚和肝素输注的患者,解读光学法aPTT结果时应考虑丙泊酚干扰可能。
- 必要时采用超速离心处理样本以去除光学干扰,但需注意报告延迟可能影响肝素剂量调整时机。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The activated partial thromboplastin time (aPTT) is a coagulation assay commonly utilized for monitoring therapeutic heparin anticoagulation. aPTT methods based on optical detection are vulnerable to spectral interference from hemolysis, icterus, lipemia, and other substances. Intravenous lipid emulsions of primarily 20% have been shown to interfere with multiple clinical laboratory assays, including those measuring aPTT by optical methods, but there is limited data on propofol's effect. The primary objective of this study was to determine the rate of interference of propofol with aPTT measurements in patients receiving both propofol and intravenous heparin. METHODS: A retrospective observational cohort study of intensive care unit patients who received concomitant propofol and heparin infusions (N = 38 patients) and whose heparin therapy was monitored by aPTT (N = 531 aPTTs) was conducted. Review of the electronic medical record was completed to obtain relevant clinical and laboratory data, while the laboratory information system was queried for analytical interference with the aPTT assay. RESULTS: A total of 109 aPTTs (21%) spanning 21 patients (55%) had documented aPTT interference. All 21 patients had at least one aPTT requiring ultracentrifugation prior to reporting, and 12 aPTTs from 4 patients were unreportable due to interference. Patients with and without aPTT interference received similar doses of propofol. None of the cases of aPTT interference were caused by hemolysis or hyperbilirubinemia. CONCLUSION: A potential medication-assay interaction was observed in approximately half of patients who received concomitant propofol and heparin infusions and had aPTT measured for anticoagulation management. Sample ultracentrifugation removes the optical interference in most cases but significantly prolongs aPTT reporting and delays appropriate adjustments to heparin dosing.
引用
- Negaard BJ, Hobbs R, Frye JR, et al. Propofol-induced interference with activated partial thromboplastin time-based monitoring of therapeutic heparin anticoagulation. Am J Health Syst Pharm. 2023. PMID: 36370416. doi:10.1093/ajhp/zxac337
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。